Andy Chen
Stock Analyst at Wolfe Research
(4.38)
# 1,300
Out of 5,126 analysts
74
Total ratings
50%
Success rate
20.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Downgraded: Hold | n/a | $120.75 | - | 4 | Oct 12, 2026 | |
| ROIV Roivant Sciences | Downgraded: Hold | n/a | $41.85 | - | 2 | Oct 12, 2026 | |
| KYMR Kymera Therapeutics | Upgraded: Buy | $180 | $134.84 | +33.49% | 5 | Sep 10, 2026 | |
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | $605 | $433.03 | +39.71% | 3 | Aug 4, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $548 → $557 | $547.03 | +1.82% | 5 | Aug 3, 2026 | |
| SYRE Spyre Therapeutics | Downgraded: Hold | n/a | $106.82 | - | 2 | Jul 28, 2026 | |
| IONS Ionis Pharmaceuticals | Downgraded: Hold | n/a | $28.33 | - | 3 | Jul 15, 2026 | |
| NTLA Intellia Therapeutics | Downgraded: Sell | $9 | $11.41 | -21.12% | 5 | Jul 15, 2026 | |
| SRPT Sarepta Therapeutics | Upgraded: Buy | $27 | $16.68 | +61.87% | 2 | Jul 8, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $44 | $30.15 | +45.94% | 4 | Jun 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $176 → $136 | $91.44 | +48.73% | 2 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $30.48 | +188.71% | 4 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $8.51 | +464.04% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $89.30 | +9.74% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $1.17 | +498.29% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $34.18 | +22.88% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $37.04 | +26.89% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $24 | $13.51 | +77.65% | 5 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $977.58 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $4.01 | n/a | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $159.85 | n/a | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $79.54 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $48.77 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $122.27 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $107.17 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $28.70 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $31.25 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $45.75 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $5.05 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.0001 | n/a | 2 | Aug 10, 2023 |
Insmed
Oct 12, 2026
Downgraded: Hold
Price Target: n/a
Current: $120.75
Upside: -
Roivant Sciences
Oct 12, 2026
Downgraded: Hold
Price Target: n/a
Current: $41.85
Upside: -
Kymera Therapeutics
Sep 10, 2026
Upgraded: Buy
Price Target: $180
Current: $134.84
Upside: +33.49%
Madrigal Pharmaceuticals
Aug 4, 2026
Upgraded: Buy
Price Target: $605
Current: $433.03
Upside: +39.71%
Vertex Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $548 → $557
Current: $547.03
Upside: +1.82%
Spyre Therapeutics
Jul 28, 2026
Downgraded: Hold
Price Target: n/a
Current: $106.82
Upside: -
Ionis Pharmaceuticals
Jul 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $28.33
Upside: -
Intellia Therapeutics
Jul 15, 2026
Downgraded: Sell
Price Target: $9
Current: $11.41
Upside: -21.12%
Sarepta Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $27
Current: $16.68
Upside: +61.87%
Celldex Therapeutics
Jun 14, 2026
Reiterated: Buy
Price Target: $44
Current: $30.15
Upside: +45.94%
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $91.44
Upside: +48.73%
Jun 2, 2026
Reiterated: Buy
Price Target: $88
Current: $30.48
Upside: +188.71%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $8.51
Upside: +464.04%
Apr 8, 2026
Reiterated: Buy
Price Target: $98
Current: $89.30
Upside: +9.74%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.17
Upside: +498.29%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $34.18
Upside: +22.88%
Apr 6, 2026
Reiterated: Buy
Price Target: $47
Current: $37.04
Upside: +26.89%
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $13.51
Upside: +77.65%
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $977.58
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $4.01
Upside: n/a
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $159.85
Upside: n/a
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $79.54
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $48.77
Upside: n/a
Mar 17, 2025
Reiterated: Buy
Price Target: $84
Current: $122.27
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $107.17
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $28.70
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $31.25
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $45.75
Upside: n/a
Oct 25, 2023
Reiterated: Buy
Price Target: $4
Current: $5.05
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.0001
Upside: n/a